DE69604071D1 - Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung - Google Patents

Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung

Info

Publication number
DE69604071D1
DE69604071D1 DE69604071T DE69604071T DE69604071D1 DE 69604071 D1 DE69604071 D1 DE 69604071D1 DE 69604071 T DE69604071 T DE 69604071T DE 69604071 T DE69604071 T DE 69604071T DE 69604071 D1 DE69604071 D1 DE 69604071D1
Authority
DE
Germany
Prior art keywords
production
therapeutic use
oxazolidinone derivatives
oxazolidinone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69604071T
Other languages
English (en)
Other versions
DE69604071T2 (de
Inventor
Samir Jegham
Frederic Puech
Philippe Burnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69604071(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9506563A external-priority patent/FR2734820B1/fr
Priority claimed from FR9506564A external-priority patent/FR2734821B1/fr
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of DE69604071D1 publication Critical patent/DE69604071D1/de
Application granted granted Critical
Publication of DE69604071T2 publication Critical patent/DE69604071T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69604071T 1995-06-02 1996-05-28 Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung Expired - Lifetime DE69604071T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9506563A FR2734820B1 (fr) 1995-06-02 1995-06-02 Derives de 3-(1,2-benzisoxazol-3-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique
FR9506564A FR2734821B1 (fr) 1995-06-02 1995-06-02 Derives de 5-methoxymethyl-3-(1,2-benzisoxazol-3-yl) oxazolidin-2-one, leur preparation et leur application en therapeutique
PCT/FR1996/000792 WO1996038444A1 (fr) 1995-06-02 1996-05-28 Derives d'oxazolidinone, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DE69604071D1 true DE69604071D1 (de) 1999-10-07
DE69604071T2 DE69604071T2 (de) 2000-04-06

Family

ID=26232004

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69604071T Expired - Lifetime DE69604071T2 (de) 1995-06-02 1996-05-28 Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung

Country Status (27)

Country Link
US (1) US5843975A (de)
EP (1) EP0835254B1 (de)
JP (1) JP3856829B2 (de)
KR (1) KR100457502B1 (de)
CN (1) CN1075072C (de)
AR (1) AR006301A1 (de)
AT (1) ATE184005T1 (de)
AU (1) AU699367B2 (de)
BR (1) BR9608896A (de)
CA (1) CA2223011C (de)
CO (1) CO4700462A1 (de)
CZ (1) CZ378497A3 (de)
DE (1) DE69604071T2 (de)
DK (1) DK0835254T3 (de)
ES (1) ES2138346T3 (de)
GR (1) GR3031710T3 (de)
HK (1) HK1014938A1 (de)
HU (1) HU224879B1 (de)
MX (1) MX9709410A (de)
NO (1) NO309091B1 (de)
NZ (1) NZ310487A (de)
PL (1) PL183919B1 (de)
RU (1) RU2164226C2 (de)
SK (1) SK281934B6 (de)
TW (1) TW360654B (de)
WO (1) WO1996038444A1 (de)
ZA (1) ZA964563B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078632A1 (de) * 1999-08-16 2001-02-28 Sanofi-Synthelabo Verwendung von Monoamin Oxydase Inhibitoren zu Herstellung eines Medikaments zur Behandlung der Fettleibigkeit
EP2140864A3 (de) * 2001-01-31 2010-01-27 H.Lundbeck A/S Verwendung von GAL3-Rezeptorantagonisten zur Behandlung von Depression und/oder Angstgefühl und Verbindungen, die in solchen Verfahren von Nutzen sind
JP4542338B2 (ja) * 2001-09-26 2010-09-15 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
JP2009525318A (ja) * 2006-02-01 2009-07-09 ファイザー・プロダクツ・インク 抗菌剤としてのベンズイソオキサゾールオキサゾリジノン
US7998992B2 (en) * 2007-03-30 2011-08-16 Institute Of Medicinal Molecular Design, Inc. Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
EP2123159A1 (de) * 2008-05-21 2009-11-25 Bayer CropScience AG (1,2-Benzisothiazol-3-yl)(thio)carbamate und (1,2-Benzisothiazol-3-yl)(thio)oxamate und deren Oxidationsformen als Pestizide
EP2513096A1 (de) * 2009-12-18 2012-10-24 Janssen Pharmaceutica, N.V. Substituierte aminothiazolonindazole als östrogenassoziierte rezeptor-a-modulatoren
AU2011218268A1 (en) * 2010-02-17 2012-09-06 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-alpha modulators
WO2016097355A1 (en) * 2014-12-19 2016-06-23 Ge Healthcare Limited Labelled oxazolidinone derivatives
DE102015012050A1 (de) * 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
RU2637643C1 (ru) * 2016-09-05 2017-12-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" (НИИФКИ) Иммунодепрессант

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653017B1 (fr) * 1989-10-17 1995-05-05 Delalande Sa Derives d'aryl-3 oxazolidinone-2, leur procede de preparation et leur application en therapeutique.
US5196543A (en) * 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
US5235063A (en) * 1989-10-17 1993-08-10 Delalande S.A. Process of preparing by condensation certain
US5182296A (en) * 1989-10-26 1993-01-26 Tanabe Seiyaky Co., Ltd. Naphthyloxazolidone derivatives
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
WO1992014418A1 (fr) * 1991-02-20 1992-09-03 Yusaku Koda Articulateur

Also Published As

Publication number Publication date
DK0835254T3 (da) 2000-03-27
MX9709410A (es) 1998-07-31
SK161497A3 (en) 1998-05-06
GR3031710T3 (en) 2000-02-29
WO1996038444A1 (fr) 1996-12-05
KR19990022187A (ko) 1999-03-25
US5843975A (en) 1998-12-01
ES2138346T3 (es) 2000-01-01
EP0835254B1 (de) 1999-09-01
CZ378497A3 (cs) 1998-04-15
NO975530D0 (no) 1997-12-01
AU699367B2 (en) 1998-12-03
RU2164226C2 (ru) 2001-03-20
PL183919B1 (pl) 2002-08-30
HU224879B1 (en) 2006-03-28
JPH11507330A (ja) 1999-06-29
HK1014938A1 (en) 1999-10-08
EP0835254A1 (de) 1998-04-15
CN1191534A (zh) 1998-08-26
NO309091B1 (no) 2000-12-11
HUP9901349A3 (en) 2000-02-28
AR006301A1 (es) 1999-08-25
HUP9901349A2 (hu) 1999-08-30
CA2223011C (en) 2007-01-09
AU6128896A (en) 1996-12-18
ATE184005T1 (de) 1999-09-15
CA2223011A1 (en) 1996-12-05
ZA964563B (en) 1996-12-12
KR100457502B1 (ko) 2005-09-05
PL323673A1 (en) 1998-04-14
DE69604071T2 (de) 2000-04-06
CN1075072C (zh) 2001-11-21
NZ310487A (en) 1999-05-28
CO4700462A1 (es) 1998-12-29
SK281934B6 (sk) 2001-09-11
TW360654B (en) 1999-06-11
NO975530L (no) 1998-02-02
JP3856829B2 (ja) 2006-12-13
BR9608896A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
DE69627411D1 (de) Triazinderivate, ihre Herstellung und Verwendung
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
ATE243682T1 (de) Heterozyklisch substituierte biphenylamid derivate, deren herstellung und deren verwendung als fungizide
DE69623992D1 (de) Derivate von dolestatin, deren herstellung und verwendung
DE69806831D1 (de) Dithiolan Derivate, deren Herstellung und deren Heileffekt
DE69529026D1 (de) Trehalose, ihre Herstellung und ihre Verwendung
DE69821623D1 (de) Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament
DE59808281D1 (de) Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel
DE69625857D1 (de) Siliconderivate, ihre Herstellung und Verwendung
DE60001451D1 (de) 1,4-diazabicyclo[3.2.2]nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
ATE231869T1 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
DE69521595D1 (de) Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69713124D1 (de) 1H-PYRIDO[3,4-b]INDOLCARBOXAMIDDERIVATE, IHRE HERSTELLUNG UND THERAPEUTISCHE VERWENDUNG
DE69604071D1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
DE69723463D1 (de) Cyclische organoselenderivate, ihre herstellung und verwendung
DE59711704D1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
DE69330075D1 (de) Oxazolinderivate, ihre Herstellung und Anwendung
DE69630391D1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
DE59606806D1 (de) Polymerholz-formkörper, ihre herstellung und verwendung
DE69514398D1 (de) 13-Substituierte Milbemycinderivate, ihre Herstellung und Verwendung
DE69327813D1 (de) Alpha-Glucosyl-Catecholaminderivate, ihre Salze, Herstellung und Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

R082 Change of representative

Ref document number: 835254

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE